Scotiabank has initiated coverage on Gilead Sciences Inc (GILD), assigning the company a Sector Outperform rating. This marks the firm's first assessment of Gilead's investment potential, reflecting their analysis of the biotechnology sector and the company's growth prospects.
Headquartered in Foster City, California, Gilead Sciences is a biopharmaceutical company focused on the research, development, and commercialization of medicines addressing unmet medical needs. The firm employs approximately 17,600 people and operates in over 35 countries worldwide. Gilead's product portfolio includes treatments for life-threatening diseases such as HIV, viral hepatitis, COVID-19, and cancer, with notable products like Biktarvy, Genvoya, and Veklury.
As of November 12, 2025, Gilead's stock is priced at $125.20, and the company boasts a market capitalization of $156.7 billion. Its trailing twelve months (TTM) price-to-earnings ratio stands at 19.32, with earnings per share (EPS) of 6.43. Gilead also offers a substantial dividend yield of 256.1%.
Analyst ratings and price targets provide insights based on extensive research and financial models. However, these assessments are subject to change as new information emerges. Investors are encouraged to consider a range of factors, including company fundamentals and industry trends, when making decisions. As of November 1, 2025, the analyst consensus for Gilead is a Buy, with 10 Strong Buy, 18 Buy, and 8 Hold ratings among 36 analysts.
Upcoming earnings reports are anticipated on April 21, 2026, with an estimated EPS of $2.07 and revenue of $7.2 billion, followed by another report on August 4, 2026, projecting an EPS of $2.22 and revenue of $7.6 billion.